ZOSTAVAX®
RECONSTITUTION USING DILUENT IN A VIAL

To reconstitute the vaccine, use only the diluent supplied since it is free of preservatives or other antiviral substances which might inactivate the vaccine.



Step 1:
To reconstitute the vaccine, first withdraw the entire contents of the diluent vial into a syringe.*





Step 2:
Inject all the diluent in the syringe* into the vial of lyophilised vaccine.



Step 3:
Gently agitate vial to mix thoroughly.

Step 4:
Withdraw the entire contents of the vial containing the reconstituted vaccine into a syringe.†



Inject the total volume of reconstituted vaccine as per the following guidelines. See product specific information.

ZOSTAVAX® is a live vaccine, please review product information and check patient eligibility before prescribing.[1]

ZOSTAVAX® vaccine screening form for contraindications can be accessed from **here**.

For subcutaneous administration.

Do not inject intravascularly.

Reconstitute immediately upon removal from the refrigerator.

It is recommended that the vaccine be administered immediately after reconstitution, to minimise loss of potency. Discard reconstituted vaccine if it is not used within **30 minutes**.

ZOSTAVAX® when reconstituted is a semi-hazy to translucent, off white to pale yellow liquid.

*Syringe not provided within packaging.

Caution: †A separate sterile needle and syringe (free of preservatives, antiseptics, and detergents) should be used for administration of ZOSTAVAX® to prevent transfer of infectious diseases and vaccine inactivation.

Storage:

Before reconstitution, protect from light.

ZOSTAVAX® should be stored refrigerated at an average temperature of 2 to 8°C until it is reconstituted for injection. **Do not freeze reconstituted vaccine.**

The diluent may be stored separately at room temperature (20 to 25°C) or in the refrigerator (2 to 8°C). **Do not freeze the diluent.**

For additional queries, please contact Seqirus Medical information on 1800 642 865.

Refer to the Australian Immunisation Handbook for recommendations for reconstitution guidelines. Consider taking appropriate measures to minimise the risk of needle stick injuries and contamination.[2]

PBS Information: ZOSTAVAX® is listed on the NIP for eligible 70 year olds, with a time limited catch-up program for eligible 71–79 year olds. Refer to the NIP and PBS Schedules.

Before prescribing, please review Product Information available at www.seqirus.com.au/products

Reference 1: ZOSTAVAX® Approved Product Information. **2.** Australian Government Department of Health. Australian Immunisation Handbook. Administration of Vaccines. available from: https://immunisationhandbook.health.gov.au/vaccination-procedures/administration-of-vaccines. Accessed July 2020.
Product Information is available from Seqirus (Australia) Pty Ltd. Tower 1, Level 12, Collins Square, 727 Collins Street, Melbourne, VIC 3008. ABN 66 120 398 067. Website: www.seqirus.com.au. Medical Information: 1800 642 865.Date of preparation: August 2020. SEQ/XCTV/0320/0047(1). 000243.

Seqirus™
A CSL COMPANY